Mutations in the renal specific Na-K-2Cl co-transporter (NKCC2) lead to type I Bartter syndrome, a life-threatening kidney disease featuring arterial hypotension along with electrolyte abnormalities. We have previously shown that NKCC2 and its disease-causing mutants are subject to regulation by endoplasmic reticulum-associated degradation (ERAD). The aim of the present study was to identify the protein partners specifically involved in ERAD of NKCC2. To this end, we screened a kidney cDNA library through a yeast two-hybrid assay using NKCC2 C terminus as bait. We identified OS9 (amplified in osteosarcomas) as a novel and specific binding partner of NKCC2. Coimmunoprecipitation assays in renal cells revealed that OS9 association involves mainly the immature form of NKCC2. Accordingly, immunocytochemistry analysis showed that NKCC2 and OS9 co-localize at the endoplasmic reticulum. In cells overexpressing OS9, total cellular NKCC2 protein levels were markedly decreased, an effect blocked by the proteasome inhibitor MG132. Pulse-chase and cycloheximide-chase assays demonstrated that the marked reduction in the co-transporter protein levels was essentially due to increased protein degradation of the immature form of NKCC2. Conversely, knockdown of OS9 by small interfering RNA increased NKCC2 expression by increasing the co-transporter stability. Inactivation of the mannose 6-phosphate receptor homology domain of OS9 had no effect on its action on NKCC2. In contrast, mutations of NKCC2 N-glycosylation sites abolished the effects of OS9, indicating that OS9-induced protein degradation is N-glycan-dependent. In summary, our results demonstrate the presence of an OS9-mediated ERAD pathway in renal cells that degrades immature NKCC2 proteins. The identification and selective modulation of ERAD components specific to NKCC2 and its disease-causing mutants might provide novel therapeutic strategies for the treatment of type I Bartter syndrome.The thick ascending limb of loop of Henle (TAL) 3 of the kidney is responsible for absorbing 20 -30% of the filtered load of NaCl (1, 2). Given that the reabsorptive capacity of downstream portions of the nephron is limited, inhibition of TAL transport capacity results in marked natriuresis and diuresis, making specific inhibitors of NaCl transport in TAL cells such as furosemide or bumetanide the most potent class of all diuretics (3). The apically located Na-K-2Cl co-transporter (NKCC2) is the pacemaker of TAL sodium chloride reabsorption (2). Hence, the activity of NKCC2 is a key determinant of final urinary salt excretion, consequently influencing long term blood pressure levels (2). This is of particular interest because changes in NKCC2 expression can be caused by several conditions such as high salt intake (4), diabetes mellitus (5), obesity (6), and aging (7). Inherited variation in the activity of NKCC2 or its regulators alters blood pressure in humans (8). Indeed, loss-offunction mutations in the NKCC2 gene, SLC12A1, cause type I Bartter syndrome (BS1), a life-threatening d...